36 results about "Complement activity" patented technology

The present invention relates to peptide, polynucleotide and fusion proteins for use as inhibitors in hemostasis. These inhibitors are members of the family of proteins bearing a collagen-like domain and a globular domain. The inhibitors are useful for promoting blood flow in the vasculature by reducing thrombogenic and complement activity. The inhibitors are also useful for pacify collagenous surfaces and modulating wound healing.

The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.

The dosages and methods described herein provide desirable pharmacokinetic (PK) and pharmacodynamics (PD) characteristics which inhibit alternative pathway complement activity, for example at least 85% or more inhibition of AP activity in vivo at dosages from about 120 mg to 200 mg BID that provides a plasma level C_trough at least about 65 ng/ml, which provides sufficient AP inhibition to reduce the risk of complement breakthrough. In addition, the dosage form described herein provides a significantly low C_max, providing additional safety margin and better dosing flexibility.

The invention belongs to the field of pharmacy, and relates to a novel application of a flavan compound in preparing anti-complement medicines. According to the invention, a modern pharmacological screening method is applied, and researches are carried out upon anti-complement active substances in plant medicines. According to the invention, the flavan compound is obtained by separation from an n-butanol extract of a commelinaceae plant commelina and an n-butanol extract of a polygonum plant fagopyrum. With an in-vitro complement activity evaluation test, it is verified that the compound has high inhibition effect upon classical pathway and alternative pathway of a complement system. The CH50 of the inhibition effect of the compound upon the classical pathway of the complement system is 0.13 (plus or minus 0.03)-0.78 (plus or minus 0.06) mM, and the AP50 of the inhibition effect of the compound upon the alternative pathway of the complement system is 0.12 (plus or minus 0.01)-1.00 (plus or minus 0.15) mM. The compound can be used for preparing anti-complement medicines.

The invention provides application of codiaceae polysaccharide to an anti-complement drug. The codiaceae polysaccharide has complement activity, and the application of the codiaceae polysaccharide refers to the application of the codiaceae polysaccharide with the complement activity to the preparation of the anti-complement drug or/and an anti-complement health-care product. The invention discovers the remarkable inhibiting function of the codiaceae polysaccharide on the classical pathway complement activity and the alternative pathway complement activity for the first time and discloses the application of the codiaceae polysaccharide to the preparation of the anti-complement drug and the anti-complement health-care product, so that the excessive activation of a complement system can be inhibited and further the certain preventive and therapeutic effects on various diseases such as systemic lupus erythematosus, rheumatoid arthritis and acute respiratory distress syndrome caused by the excessive activation of the complement system are achieved.

The invention belongs to the field of pharmacy, and relates to a new application of toluylene compounds in preparation of anticomplement medicaments. According to the invention, toluylene compounds are prepared from ethyl acetate extraction positions of roots of polygonum cuspidatum Sieb. et Zucc., and are confirmed to have strong inhibition effect on the classical pathway and the alternative pathway of the complement system by in-vitro anticomplement activity evaluation tests. The CH50 of the compounds for the inhibition effect on the classical pathway of the complement system is 110+/- 12, 250+/-20 [mu]g/ml, and the AP50 for the inhibition effect on the alternative pathway of the complement system is 800+/-25, 440+/-15 [mu]g/ml. The compounds can be used for preparation of anticomplement medicaments.

The present disclosure provides methods of treating paroxysmal nocturnal hemoglobinuria (PNH) in subjects with varying exposure to eculizumab by administering R5000. The methods include methods of switching subjects from treatment with eculizumab to R5000.

The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics.

The invention discloses a formula and a preparation method of large yellow croaker lactobacillus plantarum feed. The formula of the large yellow croaker lactobacillus plantarum feed comprises feeding feed and basal feed, wherein the feeding feed comprises 1*10<6> cfu/kg of lactobacillus plantarum, 0.1g/kg of thallus, 9.999g/kg of milk, 540g/kg fish meal, 183g/kg of starch, 37g/kg of fish paste, 20g/kg of gluten, 20g/kg of fish oil, 64g/kg of shrimp shell powder, 94g/kg of defatted soybean meal, 35g/kg of mineral mixture and 7g/kg of vitamin mixture, the percentage by mass of the feeding feed is 25.2%, and the basal feed comprises 47.3% of crude protein, 8.9% of crude fat, 10.2% of ash content and 8.4% of moisture content in percentage by mass. The preparation method comprises the following steps: carrying out separation culture, collecting the lactobacillus plantarum, mixing the defatted milk, adding the basal feed, mixing and preparing. The large yellow croaker lactobacillus plantarum feed can be used for increasing growth rate of body mass of large yellow croakers and feeding rate of the large yellow croakers, improving non-specific immunity performances such as complement activity, lysozyme activity, phagocytic activity and respiration of leukocytes in head and kidney of the large yellow croakers and enhancing pathogenic bacteria resistance and facilitates development of large yellow croaker breeding industries.

The invention belongs to the field of pharmacy, and relates to a purpose of a shikonin compound in preparing anticomplement medicines. According to the invention, the shikonin compound is extracted from an ethyl acetate extract of a boraginaceae plant arnebia euchroma (Royle) Johnst. With an in-vitro complement activity evaluation test, it is verified that the compound has high inhibition effect upon classical pathway and alternative pathway of a complement system. The CH50 of the inhibition effect of the compound upon the classical pathway of the complement system is 0.16 (plus or minus 0.02)-0.63 (plus or minus 0.09)mM, and AP50 of the inhibition effect of the compound upon the alternative pathway of the complement system is 0.24 (plus or minus 0.04)-0.41 (plus or minus 0.04)mM. The compound can be used for preparing anti-complement medicines.